Table 3 Neonatal Clinical Data for Concomitant Risk Factors Associated with Developing Osteopenia
 Variables | High ALP group (N = 52) | Low ALP group (N = 216) | p-value |
|---|---|---|---|
Duration of PN (days) ## | 8.8 ± 5.4 | 8.5 ± 5.2 | 0.69 |
Used steroids # | |||
  Yes | 14 (26.9%) | 56 (25.9%) | 0.88 |
  No | 38 (73.1%) | 160 (74.1%) | |
Used diuretics # | |||
  Yes | 36 (69.2%) | 166 (76.9%) | 0.25 |
  No | 16 (30.8%) | 50 (23.1%) | |
Used Phenobarbital # | |||
  Yes | 8 (15.4%) | 40 (18.5%) | 0.60 |
  No | 44 (84.6%) | 176 (81.5%) | |
Used Paralytic agent # | |||
  Yes | 4 (7.7%) | 10 (4.6%) | 0.37 |
  No | 48 (92.3%) | 206 (95.4%) | |
Cumulative steroid dose (mg/kg) ## | 1.1 ± 0.9 | 1.0 ± 1.1 | 0.78 |
Days of paralytic drug ## | 1.0 ± 0.0 | 1.0 ± 0.0 | - |